What is the long-term trend for MoonLake Immunotherapeutics's operating lease liabilities?

Over 3 years (2022 to 2025), MoonLake Immunotherapeutics's operating lease liabilities has grown at a 100.1% compound annual growth rate (CAGR), from -$152.43K to -$1.22M.

MoonLake Immunotherapeutics MLTX Operating lease liabilities

Operating lease liabilities at other companies

Oruka Therapeutics, Inc.ORKA

——

AnaptysBio, Inc.ANAB

——

Aurinia PharmaceuticalsAUPH

——

Apogee Therapeutics, Inc.APGE

——

Alumis Inc.ALMS

——

Mirum Pharmaceuticals, Inc.MIRM

——

Other financials

Income statement

See full

Operating income-$70.0M-47.5%

Net income-$69.7M-74.5%

EPS (diluted)-$0.98-55.6%

Balance sheet

See full

Cash & equivalents$298.5M+9.9%

Total debt$100.8M+33.3%

Total equity$254.0M-37.7%

Total assets$400.4M-21.7%

Cash flow

See full

Operating cash flow-$66.3M-73.8%

CapEx--100%

Free cash flow-$66.3M-73.6%

Valuation

See full

Market cap$1.49B-45.9%

Enterprise value$1.29B-50.0%

Returns & leverage

See full

Return on equity-77.7%-221pp

Debt / equity0.4×+0.2×

Current ratio8.6×-12.5×

Where this comes from

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about MoonLake Immunotherapeutics's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MoonLake Immunotherapeutics's operating lease liabilities?: MoonLake Immunotherapeutics (MLTX) reported operating lease liabilities of -$389K in Q1 2026.
How has MoonLake Immunotherapeutics's operating lease liabilities changed year-over-year?: MoonLake Immunotherapeutics's operating lease liabilities decreased by 52.5% year-over-year, from -$255K to -$389K.
What is the long-term trend for MoonLake Immunotherapeutics's operating lease liabilities?: Over 3 years (2022 to 2025), MoonLake Immunotherapeutics's operating lease liabilities has grown at a 100.1% compound annual growth rate (CAGR), from -$152.43K to -$1.22M.